<$BlogRSDURL$>

Thursday, October 14, 2021

Poor PR 

Moderna reaped enormous positive publicity when its COVID vaccine first came to market. That was then.  Now the company is on the defensive for failing to share enough doses with developing and Third World nations. The turnabout in PR came swiftly.  The company can still protect its reputation if it boldly and publicly ships millions of doses to the poor and needy.  A  major consideration is its manufacturing capacity.  Does it have enough?  If not, it might have to ration the US and Europe in order to ship to Africa and elsewhere.  This is something that could be hard for the company to do, especially with pending booster shots in the US.  The company is not in an enviable PR position and is faced with potentially hard choices.  


Comments:

Post a Comment

This page is powered by Blogger. Isn't yours?